Acute myelomonocytic leukemia (AMML), also known as M4 leukemia, is a subtype of acute myeloid leukemia characterized by the malignant proliferation of both granulocytic and monocytic cell lines. It is more commonly observed in elderly patients. The development of AMML may be associated with occupational factors, environmental exposures, ionizing radiation, and cytotoxic drugs. In addition to symptoms such as anemia, bleeding, and infections, patients often experience gingival hyperplasia, swelling, bleeding, ulcers, and necrosis. Skin lesions related to leukemia are also frequently observed, manifesting as diffuse maculopapular rashes, firm nodules, and masses. Furthermore, AMML can lead to proteinuria and renal insufficiency. Treatment typically involves induction therapy using the DA (daunorubicin and cytarabine) or HA (homoharringtonine and cytarabine) regimens. Once complete remission is achieved, consolidation, intensification, and maintenance therapies are required.